Russia is going to miss its target of making 30 million doses of an experimental Covid-19 vaccine this year due to setbacks maintaining the serum’s stability while expanding production.
“The main task is to scale up production,” Industry Minister
The Kremlin has pinned great hopes on the Sputnik V vaccine, which President
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.